Stay updated on LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial
Sign up to get notified when there's something new on the LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial page.

Latest updates to the LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new Revision: v3.4.2 is added and the older Revision: v3.4.1 notice is removed; these are metadata changes in the page history and do not affect study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check21 days agoChange DetectedNotice about government funding and the latest revision tag (v3.4.1) with removal of v3.4.0; these are general site updates rather than study data changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check28 days agoChange DetectedThe history page now includes a glossary toggle and color-coded change highlights (green for additions and red for deletions). It also shows update notes such as No FEAR Act Data and Revision identifiers (Revision: v3.4.0 added and v3.3.4 removed).SummaryDifference0.8%

- Check42 days agoChange DetectedThe page history shows a new revision (v3.3.4) was added and the previous revision (v3.3.3) removed, which are backend metadata updates and do not modify the study details presented on the page. They reflect version control rather than substantive updates to the record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedFooter updated to Revision: v3.3.3 and removal of HHS Vulnerability Disclosure; no core study information or functions were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page, indicating a site UI revision. This change does not modify any study data or historical records.SummaryDifference0.1%

Stay in the know with updates to LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LANRA + Gilteritinib in FLT3+ R/R AML Clinical Trial page.